• Wondering whether ICON at US$136.07 is starting to look like value again, or if the stock still carries a premium.
• The share price has moved sharply in the short term, with a 16.5% gain over the last 7 days and 20.6% over the last 30 days, yet year to date the stock is still down 27.9% and the 3 year and 5 year returns are down 38.6% and 38.3% respectively, compared with a 4.4% gain over the last year.
• Recent news flow around ICON has focused on broader sector sentiment and how contract research organizations are positioned in the current market. This helps frame these short term share price moves. For valuation, it is worth keeping that context in mind, as sentiment shifts can affect how much investors are willing to pay for the stock at any point in time.
• ICON currently has a value score of 3/6, which reflects how many of Simply Wall St's six checks indicate the stock could be undervalued. The rest of this article will walk through the key valuation approaches, before finishing with a way to tie them together into a clearer view of what the stock may be worth.

Approach 1: ICON Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock might be worth by projecting the company’s future cash flows and discounting them back to today’s value.

For ICON, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $873.5m. Analysts provide explicit forecasts for several years, and Simply Wall St then extends those estimates, with projected Free Cash Flow of about $1,134.7m in 2030. All cash flows are assessed in US$, which is also the listing currency.

Bringing these projected cash flows back to today gives an estimated intrinsic value of about $237.77 per share. Compared with the current share price of $136.07, the DCF output suggests ICON trades at a discount of about 42.8%, which in this analysis is interpreted as the stock screening as undervalued on this measure.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests ICON is undervalued by 42.8%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: ICON Price vs Earnings

For a profitable company, the P/E ratio is a useful way to check what you are paying for each dollar of earnings. It links directly to the bottom line and is widely used, so it makes comparisons straightforward.

What counts as a "normal" P/E depends on how quickly earnings are expected to grow and how risky those earnings are. Higher growth and lower perceived risk usually support a higher P/E, while slower growth or higher risk tend to justify a lower one.

ICON currently trades on a P/E of 45.43x, compared with the Life Sciences industry average of 34.27x and a peer average of 47.76x. Simply Wall St also calculates a proprietary Fair Ratio of 22.73x, which is the P/E level suggested by factors such as ICON's earnings growth profile, industry, profit margins, market capitalization and risk characteristics.

This Fair Ratio can be more informative than simple peer or industry comparisons because it adjusts for company specific traits rather than assuming all stocks should trade on similar multiples. Relative to this Fair Ratio, ICON's current P/E is higher, which points to the stock screening as overvalued on this measure.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your ICON Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as simple stories you create about ICON that link your view on its business, your forecasts for revenue, earnings and margins, and the fair value you think is reasonable. All of this happens inside Simply Wall St's Community page, where these Narratives are used by millions of investors to compare fair value with the current share price and see when their story suggests buying or selling. Each Narrative updates automatically as fresh news or earnings arrive, such as a more optimistic ICON view that lines up with a fair value around US$226.60 or a more cautious view closer to US$75.00.

For ICON however, we will make it really easy for you with previews of two leading ICON Narratives:

Fair value in this bullish narrative: US$226.60

Implied discount to that fair value versus the recent US$136.07 price: about 40.0% lower than the narrative fair value

Revenue growth assumption in this narrative: 3.2% a year

• Focus on digital tools and AI in clinical trials, with the expectation that faster, more efficient processes support revenue and margin strength.
• Assumes benefits from complex trial capabilities and past acquisitions, with ICON capturing more outsourced R&D work over time.
• Builds in risks around technology change, client concentration, acquisition integration and margin pressure that could challenge this optimistic view.

Fair value in this more cautious narrative: US$135.07

Implied premium to that fair value versus the recent US$136.07 price: about 0.7% higher than the narrative fair value

Revenue growth assumption in this narrative: 1.4% a year

• Centres on modest growth, with efficiency efforts, AI tools and partnerships helping earnings but not radically changing the trajectory.
• Assumes continued capital returns through buybacks and selective acquisitions, supported by the current balance sheet.
• Flags trial cancellations, funding constraints, competition and pricing pressure as key risks that could limit revenue and margin progress.

These two narratives show how different assumptions about growth, margins, client resilience and competition can lead to very different views of what ICON might be worth. The key step now is deciding which story lines up more closely with your own expectations and risk comfort.

Do you think there's more to the story for ICON? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.